Physician profile
Jacquelynn Witnauer
NPI 1285096321
$3,704.90
in general payments reported to CMS, 2019-2025
25 companies · $708 in 2025
The $708 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $917 · 2022: $681 · 2023: $688 · 2024: $712 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $526.60 | 2021-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $512.34 | 2021-2025 | |
| Astellas Pharma US INC | $461.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $292.59 | 2021-2024 | Xarelto |
| Amgen INC. | $229.61 | 2021-2025 | Repatha, Repatha |
| Abiomed | $206.63 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $166.45 | 2021-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.50 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $137.99 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $119.49 | 2023-2025 | Ozempic |
| Pfizer INC. | $91.98 | 2022-2025 | |
| Amarin Pharma, INC. | $89.18 | 2021-2022 | |
| Cvrx, INC. | $83.03 | 2023-2024 | Barostim Neo System |
| Abbott Laboratories | $82.94 | 2021-2025 | Jot Dx, Assurity, Merlin@Home |
| Daiichi Sankyo INC. | $78.37 | 2022-2024 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $74.37 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.99 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.46 | 2023-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $51.49 | 2025 | Assure Wcd |
| Corcept Therapeutics | $46.42 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $44.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.33 | 2021-2025 | Wainua |
| Arbor Pharmaceuticals, INC. | $35.94 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.71 | 2025 | Uptravi |
| Atricure, INC. | $18.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelynn Witnauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.